A Case of Lipoatrophy With Lispro Insulin Without Insulin Pump Therapy
- Alfonso Arranz, MD,
- Victor Andia, MD and
- Antonio López-Guzmán, MD
- From the Endocrinology Unit, Hospital Nuestra Señora de Sonsoles, Avila, Spain
- Address correspondence to Dr. Alfonso Arranz, Endocrinology Unit, Ntra. Sra. De Sonsoles, Carretera de Madrid, km 109, Avila, Spain 05071. E-mail: aarranz{at}hnss.sacyl.es
Localized lipoatrophy occurring in the subcutaneous insulin injection area in diabetic patients was a phenomenon practically forgotten after the introduction of human insulin in medical practice. In recent years, there have been very few publications in relation to this matter.
Three cases of patients with type 1 diabetes who presented with subcutaneous localized lipoatrophy areas and who were in treatment with Lispro insulin were recently reported (1,2). The three patients used a continuous subcutaneous insulin infusion (CSII) system; therefore, the authors posed the doubt of whether such an administration system locally played a determinant role in the occurrence of subcutaneous localized lipoatrophy.
We present a case of localized lipoatrophy associated with treatment with Lispro insulin administered in a multiple dose regimen that disregards the role of CSII as a necessary factor for its genesis.
Our patient is a 35-year-old woman diagnosed in January of …
